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Chronic liver disease due to hepatitis C virus (HCV) infection is a major problem in 
hemophiliacs. Recent reports suggested that hemophiliacs coinfected with hepatitis C virus 
and human immunodeficiency virus (HIV) have an increased incidence of liver failure but the 
mechanism of accelerated liver injury is not clear. We tested plasma from 100 hemophiliacs 
for anti-HCV by second generation ELISA, anti-HIV by EIA, and HCV RNA and HIV RNA 
by branched DNA and polymerase chain reaction assays to determine if hemophiliacs 
coinfected with HCV and HIV have higher HCV RNA levels and more active liver disease. 
Seventy-nine (79%) patients were anti-HCV positive, of whom 85% were HCV RNA 
positive. None of the anti-HCV-negative patients had detectable HCV RNA in plasma. 
Forty-two (42%) patients were anti-HIV positive, of whom 47% had detectable HIV RNA. 
All the anti-HIV-positive patients were also anti-HCV positive. The prevalence of both 
anti-HCV and anti-HIV increased significantly with age. There was no difference in HCV 
RNA levels between anti-HIV-positive and anti-HIV-negative patients (mean: 21 _ 4 vs 18 
- 5 Meq/ml), although HCV RNA levels were significantly higher in anti-HIV-positive 
patients with CD4 counts <200/mm 3 (P = 0.008). There was an inverse correlation between 
HCV RNA levels and CD4 counts but no correlation was found between HCV RNA and 
serum aminotransferase levels. We found a high prevalence of HCV and HIV coinfection in 
our hemophiliacs. Hepatitis C virus replication appears to be increased in patients with severe 
immunodeficiency secondary to progressive HIV infection. However, there was no correla- 
tion between HCV RNA and serum ALT level, suggesting that HCV is not directly 
cytopathic. 
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More than 50% of multitransfused hemophiliacs who 
received untreated clotting factors have chronic or 
intermittent abnormalities in liver biochemistries (1- 
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3), and up to 15% have established cirrhosis on liver 
biopsies (3-6). The predominant cause of chronic 
liver disease in hemophiliacs has now been shown to 
be due to hepatitis C virus (HCV) (7-11). It has also 
been shown that multitransfused hemophiliacs who 
received clotting factors prior to 1985 have a high 
prevalence of human immunodeficiency virus (HIV) 
infection (12). Thus, many hemophiliacs are dually 
infected with HCV and HIV. 
Three studies suggested that patients with concur- 
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rent HCV and HIV infection have an increased inci- 
dence of  liver failure compared to patients infected 
with HCV alone (13-15). Martin et al reported that 
all three patients with concurrent  HIV infection and 
non-A, non-B (NANB) hepatitis developed hepatic 
decompensation within three years of overt hepatitis 
in contrast to 8 (8.5%) of  94 patients who had NANB 
hepatitis alone (13). Eyster et al found that 8 (9%) of 
91 hemophiliacs with concurrent  HCV and HIV in- 
fection developed liver failure compared to none of 
58 hemophiliacs with HCV alone (age adjusted P = 
0.034, relative risk = 3.2) (14). Telfer  et al reported 
that the relative risk of developing liver failure was 21 
in hemophiliacs coinfected with HCV and HIV com- 
pared to hemophiliacs with HCV infection alone (15). 
However, other  factors such as age, alcohol, medica- 
tions, and concurrent  opportunistic infections second- 
ary to HIV infection may have contributed to the liver 
failure in some of these patients. Thus, the mecha- 
nism(s) by which HIV infection accelerates the pro- 
gression of HCV related liver disease is unclear. 
Several studies have now shown that patients with 
concurrent  HCV and HIV infection have higher se- 
rum HCV RNA levels, suggesting that concurrent 
HIV infection increases HCV replication (16, 17). 
Eyster et al found a significant increase in HCV RNA 
levels in anti-HCV-positive hemophiliacs who devel- 
oped superinfection with HIV and an eightfold faster 
rate of increase in HCV RNA levels during follow-up 
compared to those who remained HIV negative (17). 
They also found a negative correlation between HCV 
RNA levels and CD4 counts and a positive correla- 
tion between serum HCV RNA and aspartate ami- 
notransferase (AST) levels, suggesting that accelera- 
tion of liver disease in hemophiliacs with concurrent  
HCV  and HIV infection may be due to enhanced 
HCV  replication secondary to progressive immuno- 
deficiency. However, the correlation between serum 
HCV  RNA levels and activity of liver disease remains 
controversial (16-21). This is in part related to the 
difficulty in accurate quantitation of serum HCV 
RNA levels using polymerase chain reaction (PCR) 
assays, and the lack of longitudinal studies with ade- 
quate time points. 
This study was conducted to determine: (1) the 
prevalence of HCV and HIV infection in a cohort  of 
hemophiliacs, (2) if H C V  RNA levels are higher in 
hemophiliacs with concurrent  HIV infection and if 
there is an inverse correlation with CD4 counts, (3) if 
liver disease is more active in hemophiliacs with con- 
current HIV infection, and (4) if there is a positive 
correlation between serum A LT and HCV RNA 
levels. 
MATERIALS AND METHODS 
Patients. A total of 99 hemophiliacs and one patient with 
von Willebrand's disease who were followed at the Louisi- 
ana Comprehensive Hemophilia Care Center at Tulane 
University School of Medicine were studied. There were 99 
males and one female, with a mean age of 23.2 -+ 1.4 years, 
(range 2-65 years). None of the patients were known to 
abuse drugs or alcohol. 
Methods. Citrated plasma samples were prospectively 
collected between 1993 and 1994 and stored at -70°C prior 
to testing. All patients were tested for HCV antibody (anti- 
HCV), HIV antibody (anti-HIV), hepatitis B surface anti- 
gen (HBsAg), hepatitis B core antibody (anti-HBc), HCV 
RNA, and liver chemistries. HIV RNA and CD4 counts 
were obtained in all anti-HIV-positive patients. Anti-HCV 
was tested by ELISA-2 (Chiron Corporation, Emeryville, 
California), and quantitative HCV RNA level by the 
branched DNA (bDNA) assay (Chiron). All patients who 
had undetectable HCV RNA levels in the bDNA assay 
were retested for HCV RNA by qualitative reverse tran- 
scription-PCR assay as previously described (22). Anti-HIV 
was detected by EIA (Abbott Laboratories, North Chicago, 
Illinois), and all positive samples were confirmed by western 
blot. HIV RNA levels were quantitated by the bDNA assay 
(Chiron). The cutoffvalues for detection of HCV RNA and 
HIV RNA were 0.35 × 1 0  6 eq/ml and 1.0 × 1 0  4 eq/ml, 
respectively. HBsAg and anti-HBc were tested by ELISA 
(Abbott). Liver chemistries and CD4 counts were deter- 
mined by standard methods. Activity of liver disease was 
assessed by serum alanine aminotransferase (ALT) levels, 
as we think that it was not justifiable to perform liver 
biopsies on these patients because of the risks of bleeding 
and the extra costs of factor concentrates and prolonged 
hospital stay. 
Statistics. Group comparisons were made with Student's 
t test and chi-square test as indicated. Associations were 
made with Spearman's correlation; patients who were HCV 
RNA negative in the bDNA assay were excluded from the 
analysis. Arbitrary values were not assigned to these pa- 
tients since their true HCV RNA levels may range from 0 to 
0.34 × 1 0  6 eq/ml. 
RESULTS 
Anti-HCV was detected in 79 (79%) patients. Of 
these, 65 (82%) were positive for HCV RNA by the 
bDNA assay. Of the 14 anti-HCV-positive patients 
who had HCV RNA levels below the level of  detec- 
tion in the bDNA assay, only 2 (14%) tested positive 
for HCV RN A  by RT-PCR. None of the anti-HCV- 
negative patients was found to be H CV  RNA positive 
by the bDNA as well as the RT-PCR assays. There  
was a significant difference in age and mean ALT 
levels between anti-HCV-positive and anti-HCV- 
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TABLE 1. COMPARISON BETWEEN HCV-POSITIVE AND 
HCV-NEGATIVE PATIENTS 
Anti-HCV+ A N T I - H C V -  
(N = 79) (N = 21) 
HBV serology 
HBsAg positive 6 (7.6)* 0 (0) 
Anti-HBc 
positive 46 (58.2) 1 (4.8) 
HIV serology 
Anti-HIV 
positive 42 (53.2) 0 (0) 
Elevated ALT (N) 49 (62) 1 (4.8) 
ALT 
(units/liter) 
(mean _ SEM) 66 _ 6.2t 20 - 2.5t 
Age (yr) 
(mean +_. SEM) 27 ----. 2~: 9 --+ 1~: 
* N u m b e r s  in pa r en the se s  a re  percen tages .  
t P = 0.0002. 
~: P < 0.0001. 
negative patients (P < 0.0001 and P = 0.0002, respec- 
tively) (Table 1). 
Anti-HIV was detected in 42 (42%) patients. 
Plasma samples from 38 anti-HIV-positive patients 
were available for HIV RNA testing. Of these, HIV 
RNA was detected in 18 (47%). HBsAg was detected 
in 6 (6%) and anti-HBc in 47 (47%) patients. All the 
anti-HIV-positive and all the HBsAg-positive pa- 
tients were also anti-HCV positive. 
Fifty (50%) patients had elevated serum ALT lev- 
els, of whom only one was anti-HCV negative. This 
patient was an 8-year-old boy with severe factor 8 
deficiency and persistently elevated ALT levels. He 
was HBsAg, anti-HBc, anti-HCV, and anti-HIV neg- 
ative. 
The prevalence of both anti-HCV and anti-HIV 
increased significantly with age (P < 0.0001 and P = 
0.0004 respectively, Table 2). The prevalence of anti- 
HCV was significantly higher than that of anti-HIV 
for every age group. Among the children aged -<10 
years, 33% were anti-HCV positive but none was 
anti-HIV positive. The prevalence of anti-HCV in- 
creased rapidly to almost 100% in patients older than 
20 years, while the corresponding prevalence of anti- 
HIV increased to 60% only. 
A higher proportion of anti-HCV- and anti-HIV- 
positive patients were HCV RNA positive by the 
bDNA assay compared to the anti-HCV-positive, an- 
ti-HIV-negative patients, but the difference did not 
reach statistical significance. There was no significant 
difference in HCV RNA levels between the anti-HIV- 
positive and the anti-HIV-negative patients. How- 
ever, as can be seen in Table 3 and Figure 1, HCV 
RNA levels were significantly higher in the subgroup 
of patients with severe immunodeficiency (CD4 
counts less than 200/mm3). In addition, there was a 
significant inverse correlation between HCV RNA 
levels and CD4 counts (Figure 2). There was no 
correlation between age and HCV RNA levels (Fig- 
ure 3). This was true in both anti-HIV-positive and in 
anti-HIV-negative patients. Of  the six HBsAg- 
positive patients, only three were HCV RNA positive 
by the bDNA assay; exclusion of these three patients 
did not alter the results of the above analyses. Like- 
wise, inclusion of the two anti-HCV-positive patients 
who were HCV RNA positive in the RT-PCR assay 
but negative in the bDNA assay had no impact on the 
above analyses. 
There was no difference in the percentage of pa- 
tients with elevated ALT levels as well as the mean 
ALT levels between the HCV-positive patients with 
and without concomitant HIV infection irrespective 
of the CD4 counts (Table 3). 
There was no correlation between HCV RNA and 
ALT levels. This was true for anti-HCV- and anti- 
HIV-positive patients as well as anti-HCV-positive, 
anti-HIV-negative patients (Figure 4). 
Of the 38 anti-HIV-positive patients who were 
tested for HIV RNA, 18 (47%) were HIV RNA 
positive by the bDNA assay, 17 of whom were also 
HCV RNA positive. There was no statistical differ- 
ence in the percentage of patients who were HCV 
TABLE 2. AGE-SPECIFIC PREVALENCE OF HCV, HIV, AND HBV INFECTIONS 
Patients Anti-H CV + Anti-HIV+ HBsAg + Anti-HBc + 
Age (yr) (N) (N) (N) (N) (N) 
0-10 18 6 (33)* 0 (0) 0 (0) 1 (6) 
11-20 30 22 (73) 11 (37) 3 (10) 11 (37) 
21-30 26 25 (96) 15 (58) 1 (4) 20 (80) 
3t--40 15 15 (100) 10 (67) 2 (13) 8 (53) 
>41 11 11 (100) 6 (55) 0 (0) 7 (64) 
Total 100 79 42 6 47 
P < 0.0001 P = 0.0004 P = NS P < 0.0001 
*Numbers in parentheses are percentages. 
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TABLE 3, COMPARISON BETWEEN AtcrI-HCV+/Awn-HIV+ AND 
ANTI-HCV +/ANTI-HIV-PATIENTS 
Anti-HCV+ (N = 79) 
Anti-HlV+ 
CD 4 <200 CD 4 >200 Total An t i -HIV-  
Anti-HCV+ 
(N) 16 26 42 37 
HCV RNA+ 
[N(%)] 14 (88)* 24 (92) 37 (88)* 29 (78) 
HCV RNA 
level 35.6 + 7.7a# 13.5 4- 4.0b 21.3 _+ 4.1c 17.5 _+ 4.6d 
Meq/ml [mean 
(range)] (1.3-96.0) (0.9-90.6) (0.9-96.0) (0.4--96.0) 
Elevated ALT 
[N (%)] 8 (50) 19 (73) 27 (64) 22 (59) 
ALT (U/L), 
(mean +_ SEM) 64 +-- 13e 71 _ 9f 68 +-- 7g 63 ----- 10h 
* Includes one patient HCV RNA positive in RT-PCR assay. 
t a v s b ,  P = 0 . 0 0 8 ; a v s d ,  P = 0 . 0 4 ; b v s d ,  P = N S ; c v s d ,  P = n s ; e v s f ,  P =  NS; 
e v s h ,  P =  N S ; f v s h ,  P =  n s ; g v s h ,  P =  ns. 
RNA positive or in the mean HCV RNA levels be- 
tween the patients in whom H I V  R N A  was detected 
and those in whom HIV RNA was not detectable, 
although the numbers were too small to draw mean- 
ingful conclusions. Furthermore, there was no corre- 
lation between HCV RNA and HIV RNA levels. 
Surprisingly, there was no correlation between HIV 
RNA levels and CD4 counts, but this may again be 
related to the small sample size. 
DISCUSSION 
The prevalence of anti-HCV in our cohort of mul- 
titransfused hemophiliacs was 79%; this is in keeping 
with other published data (7-11, 14, 18). The obser- 
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Fig I.  Serum HCV RNA levels in anti-HIV-positive and anti-HIV- 
negative patients. Bars denote mean HCV RNA levels. 
vation that all anti-HIV- and all HBsAg-positive pa- 
tients were also anti-HCV positive indicates that all of 
these infections were most likely acquired through 
the same route: transfusion of clotting factor concen- 
trates. The significant increase in prevalence of anti- 
HCV, anti-HIV, and anti-HBc with age reflects not 
only an increase in the number of units of clotting 
factor concentrates received in older patients but also 
changes in donor screening and implementation of 
virus-inactivating procedures in the last decade. HB- 
sAg screening was introduced in the early 1970s, 
while anti-HIV screening began in 1985, and anti- 
HCV screening did not take place until 1990 (23-27). 
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Fig 3. Correlation between age and serum HCV RNA levels in all patients. 
ployed in the preparation of clotting factor concen- 
trates in the past 10 years, but many of the earlier 
methods were ineffective, particularly in the elimina- 
tion of non-A, non-B hepatitis (hepatitis C) (28, 29). 
Thus, effective elimination of HBV and HIV pre- 
ceded that of HCV. This accounts for the higher 
overall as well as age-specific prevalence of anti- 
HCV. The significantly lower prevalence of HBsAg 
compared to anti-HBc is related to the lower risk of 
chronicity of hepatitis B infection when acquired dur- 
ing childhood (10-20%) or adult life (<5%). In con- 
trast, almost 100% of HIV and approximately 70% of 
HCV infections progress to chronic infection (30). 
We found that most (82%) of our anti-HCV- 
positive hemophiliacs were HCV RNA positive by the 
bDNA assay. The bDNA assay is less sensitive than 
PCR assays, but it has a high degree of internal 
consistency and is a more reliable quantitative assay 
(16). Only two (14%) of our anti-HCV-positive pa- 
tients who had undetectable HCV RNA levels in the 
bDNA assay were HCV RNA positive by RT-PCR, 
supporting the validity of using HCV RNA levels by 
the bDNA assay in our correlation analyses. Some 
studies have shown that HCV RNA may be present in 
anti-HCV-negative, multitransfused patients who are 
immunosuppressed (31-33). Hepatitis C virus RNA 
was not detected in any of our anti-HCV-negative 
hemophiliacs, even when tested by the RT-PCR as- 
say. This may be related to the fact that none of our 
anti-HCV-negative patients was immunosuppressed 
by concurrent HIV infection. 
As a group, the anti-HIV-positive hemophiliacs 
had similar HCV RNA levels as the anti-HIV- 
negative ones, suggesting that HIV infection alone 
does not enhance HCV replication. This is supported 
by a lack of correlation between HCV RNA and HIV 
RNA levels, although the number of patients studied 
was small. In contrast, the anti-HIV-positive hemo- 
philiacs with severe immunodeficiency as defined by 
CD4 counts below 200/mm 3 had significantly higher 
HCV RNA levels compared to the anti-HIV-negative 
hemophiliacs as well as the anti-HIV positive ones 
who had CD4 counts above 200/mm 3. We also found 
a negative correlation between HCV RNA levels and 
CD4 counts. These findings suggest that HCV repli- 
cation is enhanced by immunodeficiency secondary to 
progressive HIV infection. This is in agreement with 
the finding of Eyster et al (17). Although the anti- 
HIV-positive patients with CD4 counts <200/mm 3 
were significantly older, the higher serum HCV RNA 
levels in these patients is probably unrelated to the 
longer duration of HCV infection, since we found no 
correlation between age and serum HCV RNA levels 
for the entire patient population or when the patients 
with and without HIV coinfection and those with 
CD4 counts above or below 200/mm 3 were analyzed 
separately. 
Fifty percent of our hemophiliacs had elevated 
ALT levels. Although we did not perform liver biop- 
sies on our patients, we suspect that most of them 
have chronic liver disease based on histological stud- 
ies of other investigators (3-6). Ninety-eight percent 
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Fig 4. Correlation between serum HCV RNA and ALT levels in anti-HIV-positive (A) 
and anti-HIV-negative (B) patients. 
of our hemophiliacs with elevated ALT levels were 
anti-HCV positive [including five patients (10%) who 
were also HBsAg positive], confirming that HCV is 
the predominant cause of liver disease in hemophili- 
acs. Thirty-eight percent of our anti-HCV-positive 
hemophiliacs had normal ALT levels despite the de- 
tection of HCV RNA in 73% of them. Some of these 
patients may have chronic liver disease since liver 
biopsies of anti-HCV-positive nonhemophiliacs with 
normal ALT levels have shown a wide range of liver 
pathology from minimal changes to chronic hepatitis 
and cirrhosis (19, 20, 34-36). Contrary to the findings 
of Eyster et al (17), we found no correlation between 
HCV RNA and ALT levels and no difference in ALT 
levels between anti-HCV-positive hemophiliacs with 
or without concurrent HIV infection irrespective of 
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the i r  C D 4  counts .  T h e  lack o f  co r re la t ion  be tween  
H C V  R N A  and  A L T  level o r  l iver his tology has also 
been  r e p o r t e d  by o t h e r  invest igators ,  suggest ing that  
H C V - i n d u c e d  liver injury may not  be due  to a d i rec t  
cy topa th ic  effect of  the virus (16, 19, 20, 33, 37, 38). 
Surpris ingly,  there  was no cor re la t ion  be tween  the 
H I V  R N A  levels and  C D 4  counts ,  a l though  the re  was 
a t r end  toward  h igher  H I V  R N A  levels with lower  
C D 4  counts .  This  may  be  re la ted  to the  smal l  n u m b e r  
of  pa t ients .  
In summary ,  we found  a high p reva lence  (79%)  of  
a n t i - H C V  in our  cohor t  o f  hemophi l iacs .  M o r e  than  
half  of  these  pa t i en t s  were  also in fec ted  with HIV.  
T h e r e  was a signif icant  increase  in the p reva lence  o f  
H C V  and H I V  infect ion with age.  H I V  infect ion on 
its own did  not  s eem to enhance  H C V  repl ica t ion ,  but  
H C V  rep l ica t ion  may  be increased  as a resul t  of  
severe  immunodef ic i ency  secondary  to progress ive  
H I V  infect ion.  W e  found  no cor re la t ion  be tween  
H C V  R N A  and  A L T  levels and  no ev idence  of  in- 
c r ea sed  activity o f  l iver d isease  as assessed by A L T  
levels in hemoph i l i ac s  with concur ren t  H I V  infect ion,  
even in those  with low CD4 counts  and  high H C V  
R N A  levels. 
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